The FDA has approved a combination drug for Helicobacter pylori infection that’s designed to address high rates of resistance to standard clarithromycin-based treatment, according to manufacturer RedHill Biopharma Ltd of Tel Aviv, Israel. In 2017, the World Health Organization designated the need for new antibiotics against H pylori as a high priority.
Voelker R. Clarithromycin-Resistant H pylori Faces New Foe. JAMA. 2019;322(21):2068. doi:10.1001/jama.2019.19479
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: